

TARGET

Intelligence Report

VOLUME XXVI No. 78

SATURDAY

April 13, 2024

**WANJIA GROUP HOLDINGS LTD:
ONE SHOULD, ALWAYS, CARRY A HANDKERCHIEF
WHEN THE WEATHER IS ICE-COLD**

After four Financial Years of booking losses, aggregating \$HK142.02 million, Wanjia Group Holdings Ltd (萬嘉集團控股有限公司) (Code: 401, Main Board, The Stock Exchange of Hongkong Ltd) managed to turn the proverbial corner, recording a Net Profit of \$HK1,938,000.00 in respect of the Financial Year, ended March 31, 2023.

With regard to the Net Profit Attributable To Shareholders of the Company, the financial results came in at \$HK1,820,000.00.

In a nutshell, Wanjia Group Holdings Ltd describes its business as follows:

‘The Company is an investment holdings company and the Group is engaged in the business on pharmaceutical wholesale and distribution business, and hemodialysis treatment and consultancy service business in the PRC (The People’s Republic of China).’*

* Hemodialysis is a treatment that removes wastes and extra fluid from one’s blood. During hemodialysis, one’s blood is pumped through soft tubes to a dialysis machine where it goes through a special filter called a dialyzer (also called an artificial kidney). Smaller waste products, such as urea and creatinine, and extra fluid, move from one’s blood through the membrane, and are removed. As one’s blood is filtered, it is returned to the blood stream. Only a small amount of blood is out of one’s body at any time’ during the process.

**THE ANNUAL REPORT OF
WANJIA GROUP HOLDINGS LTD**

The 2022-2023 Annual Report of Wanjia Group Holdings Ltd was published and disseminated in The Hongkong Special Administrative Region (HKSAR) of The People’s Republic of China (PRC) on or about Tuesday, July 25, 2023.

At Pages Five and Six of this 248-page Report, Mr Wang Jia Jun (王佳駿), designated as the Chief Executive Officer of the Company, imparted the following message to the Company's shareholders:

'RESULTS FOR THE YEAR

'The Group continued to focus on pharmaceutical wholesale and distribution business, and provides hemodialysis treatment and consultancy service business in the PRC.

'The COVID-19 pandemic restrictions in 2022 in the PRC has made it challenging for everyone but the Group's business remains robust and resilient and we are proud to see total revenue of the Group for the year was approximately HK\$173.702 million, representing an increase of approximately HK\$18.879 million as compared to 2022. The gross profit was approximately HK\$56.936 million, representing an increase of approximately HK\$2.702 million as compared to 2022. The profit for the year attributable to the owners of the Company was approximately HK\$1.820 million as a result of the continuing improvement on the Group's operation of the hemodialysis treatment and consultancy service business segment in the PRC.

'OUTLOOK AND FUTURE PROSPECTS

'The Group will centralise its resources in developing the hemodialysis treatment and consultancy service business. The Group will look to further develop its hemodialysis treatment and consultancy service business through organic growth and acquisitions.

'Looking forward, the Group will focus on developing such segment through establishment of new self-operated hemodialysis treatment centres and provide hemodialysis consultancy service to hospitals in the PRC so as to expand its operating scale and further penetrate in the market.

'The Group believes that the demand for hemodialysis treatment services in the PRC market is still far from being met and has great potential for development. Based on the Group's experience and strength in the medical field, we will continue to further explore and expand our existing businesses to further penetrate the hemodialysis sector, and it will become the driving force for building our Group's influence in the market and create better return to the shareholders.

'The Group will continue to pay attention to different investment opportunities, identify appropriate businesses and projects for shareholders, and increase shareholders returns ... '.

As at March 31, 2023, Management of the Company had a workforce, numbering 184 full-time employees, most of whom were stationed in the PRC, with emphasis on the Fujian Province.

At Page Eight of the 2022-2023 Annual Report of the Company, '**FINANCIAL HIGHLIGHTS**' were presented, hereby a verbatim copy is as follows:

- *'Total revenue was approximately HK\$173.702 million (2022: approximately HK\$154.823 million), representing an increase of approximately 12.19% over 2022.*
- *'Gross profit was approximately HK\$56.936 million (2022: approximately HK\$54.234 million), representing an increase of approximately 4.98% over 2022.*
- *'Profit from operations was approximately HK\$4.473 million (2022: loss from operations was approximately HK\$47.383 million).*
- *'Profit for the year attributable to owners of the Company was approximately HK\$1.820 million (2022: loss for the year attributable to owners of the Company was approximately HK\$50.999 million).*
- *'The basic and diluted earnings per share was approximately HK\$0.32 cents (2022: basic and diluted loss per share was approximately HK\$9.10 cents).*
- *'The Group had total cash and cash equivalents of approximately HK\$9.876 million as at 31 March 2023 (2022: approximately HK\$5.768 million).*
- *'The Board does not recommend the payment of a final dividend for the year ended 31 March 2023 (2022: Nil).'*

At ... [CLICK TO ORDER FULL ARTICLE](#)

While TARGET makes every attempt to ensure accuracy of all data published, TARGET cannot be held responsible for any errors and/or omissions.

If readers feel that they would like to voice their opinions about that which they have read in TARGET, please feel free to e-mail your views to editor@targetnewspapers.com. TARGET does not guarantee to publish readers' views, but reserves the right so to do subject to the laws of libel.